Who and Where

Who is looking at NAC in COVID?

Determination of efficacy of N-Acetylcysteine (NAC) in preventing those with mild or moderate COVID-19 from progressing to severe disease

CHA-IRB-1139-05/20

ClinicalTrials.gov ID NCT04419025

Phase

Application submission to CHA IRB May 1, 2020

Approval August 7, 2020

Enrollment September 2020

Principal Investigator (PI)

Melisa Lai-Becker MD

Enrollment Eligibility

Age >= 18 years, not pregnant at time of enrollment; known or suspect COVID-19 disease AND one or more of the following:

  • SpO2 <= 95% at rest on room air

  • SpO2 <= 90% ambulatory

  • Respiratory Rate >= 24 breaths per minute

  • Fever defined as temperature >= 100.1° Fahrenheit

  • Radiographic evidence of pulmonary pathology consistent with COVID-19

  • Use of acetaminophen (APAP, paracetamol) for symptom management of COVID-19



Kerry Blomquist RN Everett Hospital Emergency Nurse

Julie Devito PA-C Emergency Medicine Physician Assistant

Ellie Grossman MD MPH Primary Care Lead for Behavioral Health Integration; Instructor, Harvard Medical School

Lara Hall MD Family Medicine Physician; COVID-19/Respiratory Clinic Clinical Lead

Janice N. John PA-C MHS MHCDS Medical Director, Respiratory Clinic; Chief PA, Primary Care; Associate Medical Director, Assembly Square Primary Care

Rachel Hathaway MD Hospital Medicine Physician. Director, HMS Medicine Sub Internship; Director, CHA Internal Medicine Resident Evaluation; Instructor, Harvard Medical School

Duncan Kuhn MD Pulmonary & Critical Care Physician, CHA; Pulmonary & Critical Care Physician, North Shore Medical Center (Salem MA); Infectious Diseases specialist; Instructor, Harvard Medical School

Melisa Lai-Becker MD Chief, Everett Emergency Department; Director, Division of Medical Toxicology; Medical Toxicologist, Regional Center for Poison Control and Prevention Serving MA & RI; Medical Toxicologist, Boston Children's Hospital; Assistant Professor, Harvard Medical School

Mary Regan PharmD Director, Clinical and Academic Pharmacy Services; Senior Clinical Pharmacist Specialist – Critical Care; Administrator, ACPE-Accredited CPE Programming

Yamini Saravanan MD MHS Clerkship Director, HMS Primary Care; Clerkship Director, HMS Internal Medicine Clerkship; Associate Director, HMS Primary Care Experience; Instructor, Harvard Medical School

Alix Schrager MD Senior resident (PGY3), Harvard Internal Medicine Residency at CHA; Clinical Fellow in Medicine, Harvard Medical School

Tom Seufert MD Emergency Physician; Associate Director of Clinical Informatics; Director of Emergency Informatics; Instructor, Harvard Medical School


Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19

ClinicalTrials.gov Identifier: NCT04545008

Prisma Health and Clemson University

A Study of N-acetylcysteine in Patients With COVID-19 Infection

ClinicalTrials.gov Identifier: NCT04374461

Memorial Sloan Kettering Cancer Center

A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients (PRANA)

ClinicalTrials.gov Identifier: NCT04458298

Ashvattha Therapeutics (formerly Orpheris, Inc.)

Inflammatory Regulation Effect of NAC on COVID-19 Treatment (INFECT-19)

ClinicalTrials.gov Identifier: NCT04455243

King Saud University, Saudi Arabia

Clinical Application of Methylene Blue for Treatment of Covid-19 Patients (Covid-19)

ClinicalTrials.gov Identifier: NCT04370288

Mashhad University of Medical Sciences, Iran

Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu

ClinicalTrials.gov Identifier: NCT04279197

ShuGuang Hospital, Shanghai, China

Antioxidant Therapy for COVID-19 Study (GSHSOD-COVID)

ClinicalTrials.gov Identifier: NCT04466657

Obafemi Awolowo University, Nigeria